Abstract:Context: Positive health technology assessment (HTA) outcomes can have important implications for equity, efficiency and timely patient access to novel therapies. Several outcomes and dimensions of benefit beyond utility feed into HTA processes. Objective: We analyse a proprietary dataset of HTA outcomes in 7 countries, to (a) test whether HTA decision-making is grounded in welfarist or extra-welfarist approaches; and (b) empirically determine the factors associated with positive HTA outcomes, the time to achieve these and establish the magnitude of inter-country differences in assessment processes. Methods: Data were extracted from publicly available HTA reports on drugs that received marketing authorisation between 2009 and 2018 (N = 1415). The outcomes of interest were the probability of positive HTA outcomes and the time-to-HTA outcome; these were examined with respect to clinical, regulatory, product- and disease-related, evidence uncertainty and contextual variables. Econometric models utilising survival analysis and multinomial logistic regression were specified. Findings: Positive HTA outcomes accounted for 87.3% of the sample (n = 1235), of which 71% (n = 1004) were restricted. Drugs with positive HTA outcomes were subject to clinical restrictions (n = 652, 46%), financial risk-sharing (n = 439, 31%) or had been rejected at least once (n = 282, 20%). Significant predictors of positive HTA outcomes were orphan drugs with cancer indications, high quality of evidence linked to clinical and economic evidence uncertainties which had been overcome, and contextual considerations, particularly innovativeness and unmet need. Comparative analyses revealed systematic differences between countries in their propensity to accept the same drugs, particularly oncology and orphan drugs. Conclusions: Our results are contextual and reinforce arguments in favour of explicitly accounting for social value judgements, establishing separate assessment frameworks for highly uncertain products, adopting risk mitigation strategies for novel therapies with early phase evidence, and sharing of HTA practices across settings. Lastly, HTA agencies have adopted an extra-welfarist approach to value assessment and resource allocation.

Targets as a tool in health policy. Part I: Lessons learned

Law and Policy as Tools in Healthy People 2030

THE DOUBLE LIFE OF TARGETS IN PUBLIC POLICY: DISCIPLINING AND SIGNALLING IN UK ASYLUM POLICY

An evaluation of the TARGET (Treat Antibiotics Responsibly; Guidance, Education, Tools) Antibiotics Toolkit to improve antimicrobial stewardship in primary care-is it fit for purpose?

It Is Smart to Set Treatment Goals, But Are Set Treatment Goals SMART? A Qualitative Assessment of Goals Described in the Assessment of the Burden of COPD Tool

Did we learn the lesson after 60 years of Management by Objectives? A survey among former physician executives in German hospitals

Shared goals for mental health research: what, why and when for the 2020s

Controlling Prescribing through "Preferred Drug" Targets—The Bavarian Experience

Are national targets the right way to improve infection control practice?

Treating to target in multiple sclerosis: Do we know how to measure whether we hit it?

National responses to global health targets: exploring policy transfer in the context of the UNAIDS '90-90-90' treatment targets in Ghana and Uganda

Aiming for equity in children with chronic conditions: introducing a new population health management system

Acceptability of policies targeting dietary behaviours and physical activity: a systematic review of tools and outcomes

Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile

Are SMART goals fit-for-purpose? Goal planning with mental health service-users in Australian community pharmacies

Characteristics of successful government-led interventions to support healthier populations: a starting portfolio of positive outlier examples

'There's too much power in this number. It's freaking the whole response out': The views of key informants on evidence and targets to achieve hepatitis C elimination goals in Australia

Introducing health technology assessment in Tanzania

Target Trial Emulation for Evaluating Health Policy

Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges

Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries